Archive: Company News
Next-generation RNA company Inverna Therapeutics launched by Argobio and University of Southern Denmark
— Novel paradigm for therapeutics based on RNA splicing modulation
— Lead program in Huntington’s disease
Inverna Therapeutics, a novel Danish biotech company at the forefront of innovative RNA therapeutics, today announced its launch as a leading-edge RNA therapeutics company. The Company was co-founded by the University of Southern Denmark and Argobio and is dedicated to transforming patient outcomes in severe genetic diseases, starting with a lead program addressing Huntington’s disease.
tiakis Biotech AG Reports Clinical Phase Ib/II Trial Results of Tiprelestat for the Treatment of Hospitalized COVID-19 Patients
–– Tiprelestat was safe and well tolerated, with initial signs of clinical efficacy
tiakis Biotech AG, a clinical-stage biopharmaceutical company developing novel therapeutics for life-threatening pulmonary and cardiovascular diseases, today announced the results of its randomized, double-blind, placebo-controlled clinical Phase Ib/II COMCOVID trial evaluating Tiprelestat for the treatment of patients hospitalized due to COVID-19. In 2021, tiakis Biotech received support from the German Federal Ministry of Education and Research (“BMBF”) to initiate the COMCOVID trial.
Thermosome Initiates Final Dose Level in Phase I Trial of Lead Compound THE001
— Independent Data Safety Monitoring Board declared dose level 2 as safe and recommended escalation to final dose level 3
Thermosome, a drug development company focused on targeted tumor therapies, today announced its ongoing Phase I trial has progressed to dose level 3 (DL3) after the independent Data Safety Monitoring Board (DSMB) declared dose level 2 (DL2) as safe and recommended escalation to the final dose level (DL3). In the trial, the Company’s lead compound THE001is tested in patients with heavily pre-treated, locally advanced unresectable or metastatic soft tissue sarcoma (STS) in combination with regional hyperthermia. Read more…
Thermosome Presents Encouraging Initial Clinical Data from Phase I Trial of Lead Compound THE001
— THE001 safe and well tolerated in first two dose level, demonstrating encouraging signs of clinical activity
— Data presented at The Connective Tissue Oncology Society (CTOS) Annual Meeting 2024
Thermosome, a drug development company focused on targeted tumor therapies, today announced encouraging initial clinical data from the ongoing Phase I study of its lead compound THE001 in patients with heavily pre-treated, locally advanced unresectable or metastatic soft tissue sarcoma (STS). The data were presented as a poster (#P410) titled “Phase I study of THE001 (DPPG2-TSL-DOX) combined with regional hyperthermia in patients with locally advanced or metastatic soft tissue sarcoma” at The Connective Tissue Oncology Society (CTOS) Annual Meeting 2024 in San Diego, USA. Read more…